NASDAQ:CALC CalciMedica Q3 2026 Earnings Results & Report $1.42 -0.10 (-6.27%) As of 02:13 PM Eastern This is a fair market value price provided by Massive. Learn more. CalciMedica beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.24 versus the -$1.2750 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market Opens CalciMedica EPS ResultsActual EPS-$0.24Consensus EPS -$1.2750Beat/MissBeat by +$1.0350One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersCalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CalciMedica Q3 2026 Earnings FAQ Did CalciMedica beat earnings estimates for Q3 2026? CalciMedica (NASDAQ:CALC) reported earnings of -$0.24 per share for Q3 2026, beating the consensus estimate of -$1.2750. The report was announced on Tuesday, November 10, 2026. CalciMedica Earnings HeadlinesCalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesNovember 10 at 7:00 AM | globenewswire.comCalciMedica (CALC) Set to Release Earnings on WednesdayNovember 10 at 2:43 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 3, 2026 | globenewswire.comCalciMedica Inc. (CALC) - What Are Analysts Saying About This Stock?November 3, 2026 | americanbankingnews.comCalciMedica (NASDAQ:CALC) Stock Falls 16.6% - Should You Sell?October 31, 2026 | americanbankingnews.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury. The company has also investigated the candidate in other settings involving excessive inflammation, but it has not been approved for commercial use. CalciMedica is headquartered in La Jolla, California, and its development activities are conducted through clinical research programs and collaborations involving sites in the United States and other regions. The company became publicly traded on the Nasdaq Capital Market following a business combination with Graybug Vision in 2023. As a clinical-stage biotechnology company, CalciMedica’s operations remain primarily focused on research, drug development and clinical testing.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
